eCite Digital Repository

An Asian Regional Analysis of Cost-Effectiveness of Early Irbesartan Treatment versus Conventional Antihypertensive, Late Amlodipine, and Late Irbesartan Treatments in Patients with Type 2 Diabetes, Hypertension, and Nephropathy

Citation

Annemans, L and Demarteau, N and Hu, SL and Lee, TJ and Morad, Z and Supaporn, T and Yang, WC and Palmer, AJ, An Asian Regional Analysis of Cost-Effectiveness of Early Irbesartan Treatment versus Conventional Antihypertensive, Late Amlodipine, and Late Irbesartan Treatments in Patients with Type 2 Diabetes, Hypertension, and Nephropathy, Value in Health, 11, (3) pp. 354-364. ISSN 1098-3015 (2007) [Refereed Article]

DOI: doi:10.1111/j.1524-4733.2007.00250.x

Abstract

Objective: The prevalence of type 2 diabetes, often leading to diabetic nephropathy, has increased globally, especially in Asia. Irbesartan treatment delays the progression of kidney disease at the early (microalbuminuria) and late (proteinuria) stages of nephropathy in hypertensive type 2 diabetics. This treatment has proven to be cost-effective in Western countries. This study assessed the cost-effectiveness of early irbesartan treatment in Asian settings. Methods: An existing lifetime model was reprogrammed in Microsoft Excel to compare irbesartan started at an early stage to irbesartan or amlodipine started at a late stage, and standard treatments from a health-care perspective in China, Malaysia, Thailand, South Korea, and Taiwan. The main effectiveness parameters were incidences of end-stage renal disease, time in dialysis, and life expectancy. All costs were converted to 2004 US$ using official purchasing power parity. Local data were obtained for costs, transplantation,dialysis, and mortality rates. Probabilities regarding disease progression after treatment with the investigated drugs were extracted from two published clinical trials. A probabilistic sensitivity analysis was performed. Results: Early use of irbesartan yielded the largest clinical and economic benefits reducing need for dialysis by 61% to 63% versus the standard treatment, total costs by 9% (Thailand) to 42% (Taiwan), and increasing life expectancy by 0.31 to 0.48 years. Early irbesartan had a 66% (Thailand) to 95% (Taiwan) probability of being dominant over late irbesartan. Conclusion: Although the absolute results varied in different settings, reflecting differences in epidemiology, management, and costs, early irbesartan treatment was a cost-effective alternative in the Asian settings. © 2007, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Item Details

Item Type:Refereed Article
Research Division:Economics
Research Group:Applied Economics
Research Field:Health Economics
Objective Division:Health
Objective Group:Health and Support Services
Objective Field:Health Policy Economic Outcomes
Author:Palmer, AJ (Professor Andrew Palmer)
ID Code:74631
Year Published:2007
Web of Science® Times Cited:10
Deposited By:Research Division
Deposited On:2011-12-09
Last Modified:2011-12-13
Downloads:0

Repository Staff Only: item control page